Skip to content
Govbase
Govbase
Congress·In Committee·H.R. 7854

Medicines for the People Act

Rep. Tlaib Introduces Bill to Create $90 Billion Public Institute for Affordable Medicine

21 days ago·View on Congress.gov·Read full text

The Medicines for the People Act is currently in the early stages of the legislative process after being introduced in the House. It has been sent to the House Committees on Energy and Commerce and the Judiciary for review. No further actions are scheduled at this time.

Legislative Progress

House
Senate
President
Law

Key Points

  • This bill would create a brand-new government institute within the National Institutes of Health dedicated to developing drugs, devices, and biological products from start to finish — and making them available at prices ordinary people can afford.
  • The federal government would own the patents on any medicines created through this institute. Drugs manufactured by the government would be sold at cost — meaning no profit markup — and patents would be licensed for free to public and nonprofit organizations.

    From policy text

    “the Director shall ensure that the Federal Government owns the rights to any patents and trade secrets relating to drugs, devices, and biological products the research or development of which is conducted or funded under this section”
    View in full text
  • The bill authorizes a massive $90 billion for fiscal year 2027, which would fund new research facilities, clinical trials, and hiring of scientists to carry out the institute's work.

    From policy text

    “There is authorized to be appropriated to carry out this subpart $90,000,000,000 for fiscal year 2027, to remain available until expended.”
    View in full text
  • A 15-member governing board would set priorities for which diseases and health conditions to tackle first. The bill includes strict conflict-of-interest rules: no more than 5 members can come from the for-profit sector, and pharmaceutical lobbyists are banned from serving.
  • The institute would be required to share all preclinical and clinical trial data openly with researchers and the public, including cost data. All licensing agreements and contracts with private companies must also be posted online.

    From policy text

    “sharing with researchers, manufacturers, and the public preclinical and clinical trial data and data on costs in an open and timely manner”
    View in full text
  • When public manufacturing isn't practical, the institute would license patents to private manufacturers — but must give preference to nonprofit organizations before for-profit companies, and royalties would be reinvested into more research.

    From policy text

    “shall give preference to the manufacturing of such drug, biological product, or device, by a nonprofit organization before seeking any manufacturing by for-profit companies”
    View in full text
HealthcareEconomy FinanceTechnology Digital

Impact Analysis

Personal Impact

Scores: 1 = low, 5 = highSentiment: -5 to +5 (net benefit)

Milestones

2 milestones2 actions
Mar 5, 2026House

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 5, 2026

Introduced in House

What Happens Next

Projected impacts based on AI analysis

Within 180 days of enactment

Governing board must be established

The 15-member board that decides which diseases to focus on and sets institute policies would need to be in place within 6 months of the bill becoming law, starting the clock on when real work begins.

5 years after enactment

First evaluation and public report to Congress

Five years after enactment, the institute must publish its first detailed report on how many drugs it's developing, patents filed, and estimated savings to public health programs — giving the public its first look at whether the investment is paying off.

Source Information

Document Type

Congressional Bill

Official Title

Medicines for the People Act

Bill NumberHR 7854
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Read Full Bill Text

Sponsor

Cosponsors

(2)
D: 2

Analysis generated by AI. Always verify with official sources.